Fracture risk and bone mineral density in Turner syndrome
- PMID: 18415020
- DOI: 10.1007/s11154-008-9076-2
Fracture risk and bone mineral density in Turner syndrome
Abstract
Bone health is a major lifelong concern in caring for women and girls with Turner syndrome (TS). There is an approximately 25% increase in fracture risk most of which is related to medium or high impact trauma. The long bones, especially of the forearm are predominantly affected. This fact may be due to a selective cortical bone deficiency in TS which is unrelated to hypogonadism. In addition, lack of adequate estrogen replacement can lead to trabecular bone deficiency and increase in vertebral compression fractures after age 45. Evaluation of bone density by dual X-ray absorptiometry (DEXA) is important, however, it should be used judiciously in TS in view of its inherent tendency to underestimate the bone density of people with short stature. Bone size-independent methods, such as QCT or volumetric transformation of DEXA data should be used in individuals shorter than 150 cm. Achieving optimal bone density is of critical importance for fracture prevention in TS, and should be pursued by timely introduction of hormone replacement therapy, adequate dose of estrogens during the young adult life, optimal calcium and vitamin D intake and regular physical exercise. In addition, other measures to prevent fall and trauma should be considered, including optimizing hearing and vision, avoiding contact sports and exercise to improve coordination.
Similar articles
-
Fracture risk, underlying pathophysiology, and bone quality assessment in patients with Turner syndrome.Front Endocrinol (Lausanne). 2022 Oct 17;13:967857. doi: 10.3389/fendo.2022.967857. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36325455 Free PMC article. Review.
-
Monitoring and maintaining bone health in patients with Turner syndrome.Expert Rev Endocrinol Metab. 2020 Nov;15(6):431-438. doi: 10.1080/17446651.2020.1834846. Epub 2020 Oct 19. Expert Rev Endocrinol Metab. 2020. PMID: 33074770 Review.
-
Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy.Clin Endocrinol (Oxf). 1999 Oct;51(4):497-502. doi: 10.1046/j.1365-2265.1999.00841.x. Clin Endocrinol (Oxf). 1999. PMID: 10583318
-
Delay in estrogen commencement is associated with lower bone mineral density in Turner syndrome.Climacteric. 2017 Oct;20(5):436-441. doi: 10.1080/13697137.2017.1325461. Epub 2017 May 19. Climacteric. 2017. PMID: 28523940
-
Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome.Eur J Endocrinol. 2009 Aug;161(2):251-7. doi: 10.1530/EJE-09-0020. Epub 2009 May 15. Eur J Endocrinol. 2009. PMID: 19447901
Cited by
-
The Hypothesis of the Prolonged Cell Cycle in Turner Syndrome.J Dev Biol. 2022 May 11;10(2):16. doi: 10.3390/jdb10020016. J Dev Biol. 2022. PMID: 35645292 Free PMC article. Review.
-
Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies.Front Endocrinol (Lausanne). 2016 Apr 26;7:34. doi: 10.3389/fendo.2016.00034. eCollection 2016. Front Endocrinol (Lausanne). 2016. PMID: 27199891 Free PMC article. Review.
-
A preliminary study on the mechanism of skeletal abnormalities in Turner syndrome using inducing pluripotent stem cells (iPS)- based disease models.Intractable Rare Dis Res. 2019 May;8(2):113-119. doi: 10.5582/irdr.2019.01025. Intractable Rare Dis Res. 2019. PMID: 31218161 Free PMC article.
-
Association between ER-α polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment--a pilot study.J Bone Miner Metab. 2011 Jul;29(4):484-92. doi: 10.1007/s00774-010-0247-3. Epub 2011 Jan 27. J Bone Miner Metab. 2011. PMID: 21271267 Clinical Trial.
-
Clinical practice guidelines for the care of girls and women with Turner syndrome.Eur J Endocrinol. 2024 Jun 5;190(6):G53-G151. doi: 10.1093/ejendo/lvae050. Eur J Endocrinol. 2024. PMID: 38748847 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical